Update from Roche/Genentech on RG6042 Huntington’s disease global development program: Two clinical studies to begin by end of 2018

roche-genentech.png

Over the past months we and our partner Ionis Pharmaceuticals have been heavily engaged with communities around the world (patient groups, medical professionals, Health Authorities and payers) to collaborate and build the RG6042 global development programme and upcoming studies. We are eager for RG6042 to advance into further clinical development. In addition, as announced last month, the European Medicines Agency granted RG6042 PRIME (“PRIority MEdicine”) designation, which provides promising medicines enhanced interactions with the agency and the potential for accelerated evaluation.

READ THE FULL PRESS RELEASE AND LEARN ABOUT THE NEXT STEPS, ONGOING AND UPCOMING CLINICAL STUDIES FOR THE GLOBAL RG6042 DEVELOPMENT PROGRAM.